- Significant-scale randomized trial found symptoms of preventive cardiovascular effects for cocoa flavanols, together with a 27 percent reduction in the secondary endpoint of cardiovascular demise
- There was a 10 per cent reduction in overall cardiovascular situations, the trial’s major outcome, that was not statistically significant
The very first substantial-scale trial to exam the very long-term outcomes of a cocoa flavanol supplement to stop cardiovascular ailment provides promising alerts that cocoa flavanols could have protecting cardiovascular effects. In papers published in The American Journal of Clinical Nutrition, a staff led by Howard Sesso, ScD, MPH, and JoAnn Manson, MD, DrPH, both of the Division of Preventive Medicine at Brigham and Women’s Medical center, unpacks the main results of the COcoa Supplement and Multivitamin Results Research (COSMOS), a randomized, placebo-managed trial that analyzed a cocoa flavanol complement and a multivitamin in the prevention of cardiovascular ailment and most cancers. Though neither health supplement considerably diminished the key result of overall cardiovascular occasions, individuals randomized to get the cocoa flavanol health supplement had a 27 % reduce fee of cardiovascular demise, a pre-specified secondary endpoint.
“When we glance at the totality of proof for the two the key and secondary cardiovascular endpoints in COSMOS, we see promising alerts that a cocoa flavanol nutritional supplement could cut down critical cardiovascular activities, including loss of life from cardiovascular sickness,” said Sesso. “These results advantage even further investigation to greater realize the consequences of cocoa flavanols on cardiovascular health.”
“Previous studies have advised health advantages of flavanols — compounds in quite a few plant-dependent foodstuff such as cocoa, tea, grapes, and berries,” explained Manson. “COSMOS was not a chocolate demo — instead, it’s a arduous demo of a cocoa extract supplement that contains levels of cocoa flavanols that a individual could by no means realistically consume from chocolate with no introducing abnormal energy, fats, and sugar to their diet plan.”
Smaller sized, small-expression trials have identified cardiovascular positive aspects for cocoa flavanols on blood strain and blood vessel dilation. COSMOS made available the initially opportunity to analyze if a cocoa flavanol dietary supplement may well also direct to more time-term reductions in scientific cardiovascular functions. Investigators also appeared for reductions in risk of cancer. In addition, the demo was made to check a prevalent multivitamin in the avoidance of most cancers and cardiovascular disorder.
The key cardiovascular consequence for the cocoa flavanol intervention was a composite of complete cardiovascular activities, such as coronary heart assaults, stroke, coronary revascularization, cardiovascular demise, carotid artery illness, peripheral artery operation, and unstable angina. Much more than 21,000 individuals were randomized to get every day capsules that contained 500 mg cocoa flavanols (donated by DOI: 10.1093/ajcn/nqac055
“Multivitamins in the Prevention of Cancer and Cardiovascular Disease: The COSMOS Randomized Clinical Trial” by Howard D Sesso, Pamela M Rist, Aaron K Aragaki, Susanne Rautiainen, Lisa G Johnson, Georgina Friedenberg, Trisha Copeland, Allison Clar, Samia Mora, M Vinayaga Moorthy, Ara Sarkissian, Jean Wactawski-Wende, Lesley F Tinker, William R Carrick, Garnet L Anderson and JoAnn E Manson for the COSMOS Research Group, 16 March 2022, The American Journal of Clinical Nutrition.
Funding: The Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) is supported by an investigator-initiated grant from Mars Edge, a segment of Mars dedicated to nutrition research and products, which included infrastructure support and the donation of cocoa extract-containing study pills and packaging. Pfizer Consumer Healthcare (now part of GSK Consumer Healthcare) provided support through the partial provision of study pills (Centrum Silver) and packaging. COSMOS is also supported in part by grants AG050657, AG071611, EY025623, and HL157665 from the National Institutes of Health, Bethesda, MD. The Women’s Health Initiative (WHI) program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005. Neither company had a role in the trial design or conduct, data collection (other than blinded assays supported by Mars Edge and completed independently), data analysis, or manuscript preparation or review.
Disclosures: Sesso and Manson reported receiving investigator-initiated grants from Mars Edge, a segment of Mars Incorporated dedicated to nutrition research and products, for infrastructure support and donation of COSMOS study pills and packaging, and Pfizer Consumer Healthcare (now part of GSK Consumer Healthcare) for donation of COSMOS study pills and packaging during the conduct of the study. Dr. Sesso additionally reported receiving investigator-initiated grants from Pure Encapsulations and Pfizer Inc., and honoraria and/or travel for lectures from the Council for Responsible Nutrition, BASF, NIH, and American Society of Nutrition during the conduct of the study.